Clinica Medica, Department of Medical and Surgical Sciences, University of Brescia, c/o 2a Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy.
Curr Hypertens Rep. 2018 Jun 29;20(8):68. doi: 10.1007/s11906-018-0871-1.
From a physiological point of view, VEGFs (vascular endothelial growth factors) and their receptors (VEGFR) play a critical role in vascular development angiogenesis, endothelial function, and vascular tone. On the pathological side, VEGF-VEGFR signaling may induce dysregulated angiogenesis, which contributes to the growth and to the spread of tumors, being essential for neoplastic proliferation and invasion.
Pharmacological inhibition of VEGF-VEGFR is now a cornerstone in the treatment of many malignancies; however, treatment with VEGF inhibitors is commonly associated with an increase in blood pressure values. This side effect is strictly connected with the mechanism of action of these medications and might represent an index of therapy efficacy. The optimal management of this form of hypertension is, at present, not clear. Calcium channel blockers and renin-angiotensin system inhibitors probably represent the most appropriate classes of hypertensive dugs for the treatment of this condition; however, no conclusive data are presently available.
从生理学角度来看，VEGFs（血管内皮生长因子）及其受体（VEGFR）在血管发育、血管生成、内皮功能和血管张力中起着关键作用。在病理方面，VEGF-VEGFR 信号可能会诱导失调的血管生成，这有助于肿瘤的生长和扩散，对肿瘤的增殖和侵袭至关重要。
VEGF-VEGFR 的药理学抑制现已成为许多恶性肿瘤治疗的基石；然而，VEGF 抑制剂的治疗通常与血压值升高有关。这种副作用与这些药物的作用机制密切相关，可能是治疗效果的指标。目前，这种形式的高血压的最佳治疗方法尚不清楚。钙通道阻滞剂和肾素-血管紧张素系统抑制剂可能是治疗这种疾病的最适宜的降压药物类别；然而，目前尚无确凿的数据。
